Fabio Guolo, MD, University of Genoa, Genoa, Italy, comments on the real-world efficacy of CPX-351 in secondary acute myeloid leukemia (AML), as defined by the WHO 2022 classification. The study found no significant difference in complete response (CR) rates and survival outcomes between the real-world and clinical trial settings. Dr Guolo also mentions that, when compared with historical data from patients treated with an intensified fludarabine regimen, CPX-351 showed improved responses and reduced toxicity. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
